ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors

Andrea Lombardi, Simona Landonio, Carlo Magni, Stefania Cheli, Cristina Mazzali, Mario U. Mondelli, Giuliano Rizzardini, Emilio Clementi, Felicia Stefania Falvella

Research output: Contribution to journalArticle

Abstract

Chronic hepatitis C is one of the most important causes of liver disease, leading to cirrhosis, hepatic decompensation and hepatocellular carcinoma. Recently some important advances in therapy have been achieved with the introduction of first wave, first generation direct acting antiviral agents (DAAs) such as boceprevir (BOC), in combination with pegylated interferon (Peg-IFN) and ribavirin (RBV). The superior rate of sustained virological response with this treatment is accompanied by an elevated frequency of anaemia. Several studies have evidenced the importance of single nucleotide polymorphisms (SNPs) in inosine triphosphatase (ITPA) and solute carrier family 29, member 1 (SLC29A1) genes in the development of this adverse event. Here, we investigated haemoglobin levels and the best-known functional SNPs in ITPA and SLC29A1 genes in 22 patients treated with triple therapy with BOC/Peg-IFN/RBV. The identification of ITPA protective and SLC29A1 risk genotypes still appears to be a current methodology in RBV dosing during hepatitis C virus therapy with DAAs.

Original languageEnglish
Pages (from-to)163-166
Number of pages4
JournalPharmacology
Volume96
Issue number3-4
DOIs
Publication statusPublished - Sep 8 2015

Keywords

  • Genotyping
  • Hepatitis C therapy
  • ITPA
  • Ribavirin
  • SCL29A1

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors'. Together they form a unique fingerprint.

  • Cite this

    Lombardi, A., Landonio, S., Magni, C., Cheli, S., Mazzali, C., Mondelli, M. U., Rizzardini, G., Clementi, E., & Falvella, F. S. (2015). ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. Pharmacology, 96(3-4), 163-166. https://doi.org/10.1159/000438486